Helicos BioSciences Corp., a genetic analysis technologies firm, said on Wednesday it is planning an initial public offering of as much as $100 million in common stock. According to a preliminary offering document filed with the U.S. Securities and Exchange Commission, the Cambridge, Massachusetts-based company said it is seeking a NASDAQ listing under the symbol "HLCS."